1 / 62

The Design, Synthesis, and Evaluation of Mechanism-Based b - Lactamase Inhibitors

The Design, Synthesis, and Evaluation of Mechanism-Based b - Lactamase Inhibitors. CWRU 2009. Major Classes of b - Lactam Antibiotics. Potent, broad-spectrum antibiotics Usually well tolerated

lorand
Download Presentation

The Design, Synthesis, and Evaluation of Mechanism-Based b - Lactamase Inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Design, Synthesis, and Evaluation of Mechanism-Based b-Lactamase Inhibitors CWRU 2009

  2. Major Classes of b-Lactam Antibiotics • Potent, broad-spectrum antibiotics • Usually well tolerated • Structural similarities include a negatively charged carboxylate, (usually fused bicylic) b-lactam, and C6 appendage

  3. The b-lactam antibiotics interfere with one or more members of a crucial set of bacterial enzymes, known as the penicillin-binding-proteins (PBPs), that are responsible for cross-linking glycan strands through a protruding peptide side chain.

  4. The b-lactam antibiotics are believed to resemble the D-Ala-D-Ala terminus of the pentapeptide side chain (StromingerHypothesis) • Bacterial transpeptidases cleave between the two D-Ala residues, to form an intermediate acyl-enzyme, which is then reacted with a free amino moiety (e.g. the w amino group of diaminopimelic acid) to form the cross link.

  5. Link

  6. Why are b-lactam antibiotics such good drugs? • b-Lactamantbiotics still comprise approximately half the commercial antibiotic market. • Formation of a covalent bond to the target(s) may be an effective strategy for avoiding resistance due to point mutations which lower affinity • Targeting the bacterial cell wall avoids the necessity to accumulate in cytoplasm, thus avoiding efflux pumps. • b-lactams do not penetrate most mammalian cell types, resulting in low toxicity (disadvantage when treating atypicals) • Most commonly observed resistance is due to production of b-lactamase(s)

  7. Resistance to b-Lactam Antibiotics Production of one or more enzymes (b-lactamases) that hydrolytically destroy b-lactam antibiotics Produce PBPs that do not recognize penicillin In the case of Gram-negative strains delete outer membrane porins, which are responsible for the allowing the b-lactams to reach the periplasm and hence the cell wall In the case of Gram-negative strains, upregulate efflux pumps, which are responsible for pumping out foreign substances (including b-lactams). Action of Serine b-Lactamases

  8. The b-Lactamases • More than 600 different b-lactamases, grouped into four classes A-D • Classes A, C, and D are serine enzymes • Class B are zinc metalloenzymes • Historically, the class A (serine) enzymes were the most prominent • Can be produced in large quantity (hyperexpressed) • Produced in the periplasm of Gram-negative organisms, or extracellularly in Gram-positive strains.

  9. Bulky group Enzyme • One early strategy for countering b-lactamase mediated resistance was to design b-lactam antibiotics which would also be poor b-lactamase substrates. • This was achieved by incorporating sterically large substituents at C6 (penicillin) or C7 (cephalosporin).

  10. Methicillin-resistant Staphylococcus aureus MRSA • Unfortunately, this gave rise to new forms of resistance, such as the appearance of a penicillin binding protein with reduced affinity for all b-lactam antibiotics (PBP2a in MRSA) and also the appearance of b-lactamases with enlarged active sites (extended spectrum b-lactamases or ESBLs) that could accommodate the larger antibiotics.

  11. Recent Trends in b-Lactamase-mediated Resistance • Broad spectrum b-lactamases, known as extended spectrum b-lactamases (ESBLs) capable of hydrolyzing third generation cephalosporins, are disseminated widely (e.g. class A, CTX-M) • Class C b-lactamases (AmpC) are more widely disseminated, now including many plasmid-mediated AmpCs (e.g. FOX and CMY) • Classes A and D enzymes have evolved the ability to hydrolyze the carbapenem class of antibiotics. These serine carbapenemases are increasingly widespread (e.g. KPC). • Class B metallo-b-lactamases are disseminating widely. These enzymes were originally seen in Asia and in Europe, but cases of resistance due to class B b-lactamases are now appearing in the US (e.g. IMP and VIM).

  12. Current Commercial b-Lactamase Inhibitors • A second approach was to develop inhibitors of b-lactamase • Unfortunately, current commercial inhibitors target only class A enzymes

  13. Since the inhibitors have no independent antibacterial activity (i.e. ability to bind PBPs), they must be coadministered with b-lactam antibiotics

  14. How do these commercial inhibitors work? • Placing sulfur at the sulfone oxidation state predisposes the thiazolidine ring to fragment, producing the iminium ion shown above. • The iminium ion can then tautomerize to the b-aminoacrylate, or be captured by a second active site serine, producing in both cases, a stabilized acyl-enzyme.

  15. How can we build a better mousetrap? Irreversible inhibitors offer numerous opportunities for improving the inhibitory efficiency.

  16. The Inhibitor Design Process enzymatic mechanism active site dimensions and binding characteristics synthetic feasibility generate a library of prospective inhibitors Assay against all relevant enzymes

  17. Initially we focused on designing inhibitors which held the potential to quickly form very stable acyl-enzymes. Focus Here

  18. IC50 Values against the class C b-lactamase derived from Enterobacter cloacae, strain P99

  19. Further mechanistic investigations uncovered an isotope effect on the rate of inactivation. A mechanism consistent with this observation is shown below. Stabilized Acyl-Enzyme

  20. New chemical methodology facilitated the preparation of new inhibitors.

  21. The availability of 6-oxopenicillanate simplifies the synthesis of 6-alkylidene penams, as shown.

  22. Buynak, J. D. et. al. BMCL 1999, 9, 1997-2002.

  23. Initial attempts to improve the cephalosporin series of b-lactamase inhibitors relied on analogy with the cephalosporin antibiotics themselves.

  24. But these efforts resulted in an abysmal failure!

  25. Since the charge neutral pyridine moiety is a better leaving group than the negatively charged acetate, it is more likely to follow pathway 1 above. • Yet all the inhibitory mechanisms we have proposed follow pathway 2.

  26. How do my inhibitors work? • Intramolecular capture of intermediate imine is more efficient than intermolecular capture (and/or tautomerization) • Inhibitors tend to be more general to all (serine) b-lactamases, since inhibitory mechanism does not depend on enzyme active site groups

  27. Next goal: Prepare penicillin-derived inhibitors of metallo-b-lactamases Problem: Metallo-b-lactamases are still a small portion of total number of b-lactamase producing strains Solution: Prepare a single molecule that can function as dual inhibitor of both metallo- and serine-b-lactamases. Problem: Metallo and serine b-lactamases have profoundly different mechanisms of action.

  28. Proposed series of events involved in the hydrolysis of a cephalosporin substrate by the L1 metallo-b-lactamase.

  29. Inhibiting metallo-b-lactamases Like most metalloenzymes, metallo-b-lactamases are inactivated by good zinc chelators. Potential problem is that zinc chelating agents would likely be nonspecific, thus resulting in toxicity. Solution: Generate a zinc chelating moiety that relies on the action of the enzyme itself to achieve optimal inhibitory activity (i.e. generate a mechanism-based metalloenzyme inhibitor).

  30. Proposed Mechanism-based Inhibitors of the Zinc Metallooenzymes

More Related